
PKBO
Healthcare · Biotechnology · $520,310 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 28, 2024 | Time not confirmed | — | -0.09 | — |
| May 29, 2024 | Time not confirmed | — | -0.11 | — |
| Feb 28, 2024 | Time not confirmed | — | -0.02 | — |
| Nov 29, 2023 | Time not confirmed | — | 0.01 | — |
| Aug 30, 2023 | Time not confirmed | — | -0.29 | — |
| May 31, 2023 | Time not confirmed | — | -0.34 | — |
| Mar 1, 2023 | Time not confirmed | — | -0.75 | — |
| Nov 30, 2022 | Time not confirmed | -0.46 | -0.02 | +95.7% |
| Aug 16, 2022 | After the close | — | -0.07 | — |
| May 20, 2022 | After the close | — | 0.08 | — |
| Mar 31, 2022 | After the close | — | -0.12 | — |
| Nov 15, 2021 | Time not confirmed | — | 0.02 | — |
| Jul 26, 2021 | Time not confirmed | — | -0.05 | — |
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company's lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an…